- Other Names
- C9orf26, IL1F11, NFHEV, DVS 27
- Ave. Rating
- Submit a Review
- Product Citations
- publications
![Human_IL-33_CF_GMP-RECOM_1_112421 Human_IL-33_CF_GMP-RECOM_1_112421](https://d1spbj2x7qk4bg.cloudfront.net/Admin/Public/GetImage.ashx?Image=/Files/Images/media_assets/products/product_images/Human_IL-33_CF_GMP-RECOM_1_112421.png&Width=240&Height=300&altFmImage_path=&Compression=90&Crop=5)
-
GMP recombinant human IL-33 induces dose-dependent proliferation of D10.G4.1 cells. Deep Blue Cell Viability™ Kit (Cat. No. 424701) is used to measure the proliferation. The ED50 range for this effect is 0.1 - 0.5 ng/mL.
Cat # | Size | Price | Save |
---|---|---|---|
581814 | 25 µg | ¥96,800 | |
581816 | 100 µg | ¥264,440 |
Select size of product is eligible for a 40% discount! Promotion valid until September 30, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
IL-33 belongs to the IL-1 family and is closely related in structure to IL-18 and IL-1β. IL-33, IL-1β, and IL-18 are synthesized as biologically inactive precursors and are cleaved by the enzyme caspase-1 to be secreted as active mature forms. IL-33 stimulates target cells by binding to the IL-1R/TLR superfamily member ST2 and, subsequently, activates NF-κβ and MAPK pathways via identical signalling events to those observed for IL-1β. In addition, IL-33 is a nuclear factor (NF-HEV) abundantly expressed in high endothelial venules from lymphoid organs that associate with chromatin and exhibit transcriptional regulatory properties.
Product DetailsBioLegend Cell-Vive™ GMP Recombinant proteins are manufactured and tested in accordance with USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Ph. Eur. Chapter 5.2.12 in a dedicated GMP facility compliant with ISO 13485:2016. Specifications and processes include:
- Low endotoxin level (≤ 0.1 EU/μg)
- Purity (≥ 95% or higher)
- Bioburden testing
- Mycoplasma testing
- Batch-to-batch consistency
- Vendor qualification
- Raw material traceability and documentation
- Documented procedures and employee training
- Equipment maintenance and monitoring records
- Lot-specific certificates of analysis
- Quality audits per ISO 13485:2016
- QA review of released products
Product Details
- Source
- Human IL-33, amino acids Ser112-Thr270 (Accession# NM_ 033439) was expressed in E. coli.
- Molecular Mass
- The 159 amino acid recombinant protein has a predicted molecular mass of approximately 18 kD. The DTT-reduced protein migrates at approximately 19 kD and non-reduced protein migrates at approximately 20 kD by SDS-PAGE. The N-terminal amino acid is Serine.
-
N-terminal
Sequence Analysis - Ser-Ile-Thr-Gly-Ile-Ser-Pro-Ile-Thr-Glu
- Purity
- ≥ 95%, as determined by Coomassie stained SDS-PAGE
- Formulation
- 0.1 µm filtered protein solution is in PBS, 1 mM EDTA, 2 mM TCEP
- Endotoxin Level
- Less than or equal to 0.1 EU per μg protein as determined by the LAL method
- Residual Host Cell Protein Content
- ≤ 0.500 ng/μg by ELISA
- Concentration
- 500 µg/mL
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week or stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- ED50 = 0.1 - 0.5 ng/mL as determined by the dose-dependent stimulation of D10.G4.1 cell proliferation. Deep Blue Cell Viability™ Kit (Cat. No. 424701) is used to measure the proliferation.
- Application
-
Bioassay
Cell Culture - Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
- Disclaimer
-
BioLegend Cell-Vive™ GMP Recombinant proteins are for research use only. Suitable for ex vivo cell processing. Not for injection or diagnostic or therapeutic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.
Antigen Details
- Structure
- Cytokine
- Distribution
-
IL-33 mRNA is expressed in a broad range of human tissues, such as heart, small intestine, brain, ovary, testis, pancreas, and colon. Higher IL-33 expression was detected in human keratinocyte, fibroblast, myocyte, and alveolar cells
- Function
- IL-33 drives production of Th2-associated cytokines from in vitro polarized Th2 cells. In mice, IL-33 injection induced the expression of IL-4, IL-5, and IL-13 and led to severe pathological changes in the lung and the digestive tract. In addition, IL-33 acts as a chemoattractant for Th2 cells, both in vitro and in vivo. TNF-α and IL-1β are activators of IL-33 transcription in fibroblasts and keratinocytes.
- Interaction
- Th2 cells, mast cells, basophils, eosinophils and natural killer cells
- Ligand/Receptor
- IL-1 family receptor T1/ST2 and IL-1RAcP (IL-1 receptor associated protein).
- Bioactivity
- Measured by its ability to induce proliferation of D10.G4.1 cells.
- Biology Area
- Cell Biology, Immunology, Stem Cells, Transcription Factors
- Molecular Family
- Cytokines/Chemokines
- Antigen References
-
- Schmitz J, et al. 2005. Immunity. 23:479-90.
- Barksby HE, et al. 2007. Clin Exp Immunol. 149:217-25.
- Arend WP, et al. 2008. Immunol Rev. 223:20-38.
- Suzukawa M, et al. 2008. J Immunol. 181:5981-9.
- Moussion C, et al. 2008. PLoS One. 3:e3331.
- Mildner M, et al. 2010. Cardiovasc Res. 87:769-77.
- Gene ID
- 90865 View all products for this Gene ID
- UniProt
- View information about IL-33 on UniProt.org
Follow Us